Young Whang, MD
Hematology & Oncology · Chapel Hill, NCNPI 1285796615
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $9,560 of the $9,560 with a category attached, or 100.0%. Janssen Research & Development, LLC accounts for 84.3% of it on its own, with 1 other manufacturer making up the rest. Reporting peaked in 2022 at $4,960 and has fallen 69.8% since, to $1,500 in 2024.
Across 6 payments — averaging $1593.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Research & Development, LLC$8K
- Telix Pharmaceuticals$2K
Across 75 payments — averaging $4635.65 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Clovis Oncology, Inc.$220K
- Amgen$45K
- Pharmaand GmbH$41K
- Novartis$34K
- Astellas Pharma Global Development$8K
What the payments were for
- Consulting fees$9,560100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Research & Development, LLC | 5 | $8,060 |
| Telix Pharmaceuticals | 1 | $1,500 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ILLUCCIX$3,000
How this compares
$9,560 in reported general payments places this provider in the 75th percentile of 358 hematology & oncology providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NubeqaDarolutamide | 121 | $1,595,789 |
| XtandiEnzalutamide | 34 | $447,106 |
| Abiraterone Acetate | 92 | $102,877 |
| OrgovyxRelugolix | 18 | $45,821 |
| EliquisApixaban | 31 | $17,981 |
| Gabapentin | 37 | $836 |
| Prednisone | 135 | $681 |
| Tamsulosin Hcl | 18 | $426 |
| Prochlorperazine Maleate | 17 | $233 |
| Potassium Chloride | 14 | $189 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 13 | $157 |
| Dexamethasone | 25 | $121 |
| Levothyroxine Sodium | 19 | $113 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $41 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Chapel Hill
- Jared WeissChapel Hill$217K
- Joshua ZeidnerChapel Hill$208K
- Brandi ReevesChapel Hill$198K
- Nigel KeyChapel Hill$174K
- Norman SharplessChapel Hill$125K
- Lisa CareyChapel Hill$51K
- Alice MaChapel Hill$42K
- Thomas SheaChapel Hill$24K
- Juneko Grilley OlsonChapel Hill$24K
- Amit MehtaCary$4.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.